Omeros (OMER) Stock Forecast & Price Target

Omeros is viewed favorably because Yartemlea’s launch is showing unusually strong early traction, including $28.5M of sales in 2Q, $11.1M of gross revenue and $9.9M of net revenue in 1Q26, with all 175 U.S. transplant centers detailed, 30 accounts ordering by quarter-end, 60% of the top 10 centers obtaining P&T approval, and all prior-authorization requests approved to date. The bull case is further strengthened by the fact that roughly 75% of Yartemlea orders have been for adults, suggesting rapid penetration into the larger adult transplant market rather than a slower pediatric-led rollout, while the permanent J-code effective July 1 and NTAP beginning October 1 should reduce reimbursement friction and improve hospital economics. On a fundamental basis, the company’s MASP-2/complement platform and partner-backed value creation support the thesis, with risk-adjusted peak Yartemlea sales raised to about $400M, Europe treated as upside rather than core to the case, and the Novo Nordisk transaction adding non-dilutive value potential and balance-sheet support.

Omeros is viewed negatively because the negative CHMP opinion for YARTEMLEA removes the EU opportunity from the model, creates a near-term overhang, and highlights regulatory uncertainty that could extend across the pipeline, even if the firm argues the U.S. thesis remains intact. The company still faces significant commercialization risk, since bundled hospital payment may not fully cover incremental drug costs and NTAP reimbursement only partially offsets the economics, leaving adoption dependent on real-world uptake in transplant centers rather than a clean reimbursement environment. Although the U.S. launch remains the main value driver and management has pointed to roughly $400M in peak sales with minimal Europe contribution, the stock may stay range bound until 2Q26 U.S. sales or the AZN/Alexion TA-TMA data, while development, regulatory, and pipeline failures remain key threats to profitability and valuation.